Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage
Stroke 25:2315-2328, Mayberg,M.R.,et al, 1994
Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors
Stroke 52:3121-3131, Grimaldi-Bensouda, L.,et al, 2021
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events with Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients with Atrial Fibrillation with a History of Intracranial Hemorrhage
JAMA Network Open 3:e206424, Tsai, C.T.,et al, 2020
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Improved Stroke Prevention in Atrial Fibrillation after the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 49:2122-2128, Forslund, T.,et al, 2018
Pregnancy, Hormonal Treatments for Infertility, Contraception, and Menopause in Women After Ischemic Stroke
Stroke 48:501-506, Caso, V.,et al, 2017
Optimal Timing of Anticoagulant Treatment after Intracerebral Hemorrhage in Patients with Atrial Fibrillation
Stroke 48:314-320, Pennlert, J.,et al, 2017
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant
J Stroke Cerebrovasc Dis 26:2976-2980, Nam, K.W.,et al, 2017
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Outcomes with Edoxaban Versus Warfarin in Patients with Previous Cerebrovascular Events
Stroke 47:2075-2082, Rost, N.S.,et al, 2016
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014
Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014
Stroke Patients with Suspected Atrial Fibrillation Should be Started on Anticoagulation Pending the Results of Long-Term Cardiac Monitoring
Stroke 44:298-299,302, Diener, H., 2013
Stroke Patients with Suspected Atrial Fibrillation Should NOT be Started on Anticoagulation WHILE AWAITING the Results of Long-Term Cardiac Monitoring
Stroke 44:300-301,302, Katsnelson, M. & Sacco, R., 2013
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013
Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013
Edoxaban Versus Warfarin in Patients with Atrial Fibrillation
NEJM 369:2093-2104, Giugliano, R.P.,et al, 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Critique of Apixaban Versus Warfarin in Patients with Atrial Fibrillation
Stroke 43:922-923, Nedeltchev,K, 2012
Antiplatelets vs Anticoagulation for Dissection
Neurol 79:686-689, Kennedy, F.,et al, 2012
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial
Lancet 380:1749-1758, Lopes, R.,et al, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012
Management of Anticoagulation Before and After Elective Surgery
www.uptodate.com Dec. 2012, Lip, G. & Douketis, J., 2012
Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation
Stroke 42:112-118, Mercaldi,C.J.,et al, 2011
New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF
JAMA 305:25-26, Mitka,M., 2011
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011
Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010